^
Association details:
| Biomarker: | KDM6A mutation |
|---|---|
| Cancer: | Gastric Cancer |
| Drug: | 5-fluorouracil (Thymidylate synthase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
[KDM6A mutation and expression in gastric cancer are associated with prognosis]
Published date:
08/23/2020
Excerpt:
The analysis result of Kaplan Meier-Plotter database showed that, among all of the 875 patients, 655 patients had low KDM6A expression and 220 patients had high expression...In male, gastric cancer patients with stage Ⅲ, intestinal type, diffuse type, simple surgical treatment and fluorouracil chemotherapy, the expression of KDM6A is related to the patient's overall survival time (all P<0.05).
DOI:
10.3760/cma.j.cn112152-20190528-00334
Source:
Title:
[KDM6A mutation and expression in gastric cancer are associated with prognosis]
Published date:
08/23/2020
Excerpt:
CONTRADICTING EVIDENCE: In male, gastric cancer patients with stage Ⅲ, intestinal type, diffuse type, simple surgical treatment and fluorouracil chemotherapy, the expression of KDM6A is related to the patient's overall survival time (all P<0.05)….The survival time of gastric cancer patients with KDM6A mutation or low expression is shorter.
DOI:
10.3760/cma.j.cn112152-20190528-00334
